NCT01613950View on ClinicalTrials.gov

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
Interventions
DRUG

AUY922

AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).

DRUG

BYL719

BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.

Trial Locations (9)

6500

Novartis Investigative Site, Bellinzona

10048

Novartis Investigative Site, Taipei

50924

Novartis Investigative Site, Cologne

97080

Novartis Investigative Site, Würzburg

02114

Massachusetts General Hospital Mass General 2, Boston

77030-4009

University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology, Houston

Unknown

Novartis Investigative Site, Chuo-ku

110 744

Novartis Investigative Site, Seoul

738-736

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY